// App-Quantinova.ai

TPS192 : A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

Researchers

Presenter

  • Dhruv Bansal

Principal Investigators

  • Rachel Beck

  • Vivek Arora

  • Eric Marshall Knoche

  • Joel Picus

  • Melissa Andrea Reimers

  • Bruce J. Roth

  • James L. Gulley

  • Robert Schreiber

  • Russell Kent Pachynski

Medical Centers

  • Division of Oncology, Washington University School of Medicine, St. Louis, MO

  • Washington University School of Medicine, Division of Oncology, St. Louis, MO

  • Genitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD

  • Department of Pathology and Immunology, and Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • PROSTVAC-V/F

  • Ipilimumab

  • Docetaxel

  • Nivolumab

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT03532217

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved